Eva Kimani
Overview
Explore the profile of Eva Kimani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimani D, Jagne Y, Cox M, Kimani E, Bliss C, Gitau E, et al.
Mol Ther
. 2014 Jun;
22(11):1992-2003.
PMID: 24930599
To induce a deployable level of efficacy, a successful malaria vaccine would likely benefit from both potent cellular and humoral immunity. These requirements are met by a heterologous prime-boost immunization...
2.
Gitau E, Tuju J, Karanja H, Stevenson L, Requena P, Kimani E, et al.
J Immunol
. 2014 Jan;
192(4):1753-61.
PMID: 24453249
The immune response against the variant surface Ag Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a key component of clinical immunity against malaria. We have investigated the development and...
3.
Ogwang C, Afolabi M, Kimani D, Jagne Y, Sheehy S, Bliss C, et al.
PLoS One
. 2013 Mar;
8(3):e57726.
PMID: 23526949
Background: Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell...
4.
Gitau E, Tuju J, Stevenson L, Kimani E, Karanja H, Marsh K, et al.
PLoS One
. 2012 Jan;
7(1):e30095.
PMID: 22272280
The Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a variant surface antigen expressed on mature forms of infected erythrocytes. It is considered an important target of naturally acquired immunity....